Teachers Advisors LLC lifted its holdings in shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) by 14.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,098 shares of the biopharmaceutical company’s stock after purchasing an additional 1,305 shares during the quarter. Teachers Advisors LLC owned 0.14% of BioSpecifics Technologies Corp worth $500,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. AJO LP bought a new position in shares of BioSpecifics Technologies Corp during the second quarter worth approximately $501,000. Eagle Asset Management Inc. increased its holdings in shares of BioSpecifics Technologies Corp by 0.6% during the second quarter. Eagle Asset Management Inc. now owns 182,206 shares of the biopharmaceutical company’s stock worth $9,021,000 after purchasing an additional 1,039 shares during the period. Chicago Equity Partners LLC increased its stake in BioSpecifics Technologies Corp by 0.8% in the second quarter. Chicago Equity Partners LLC now owns 13,225 shares of the biopharmaceutical company’s stock valued at $655,000 after acquiring an additional 110 shares during the last quarter. Prudential Financial Inc. increased its stake in BioSpecifics Technologies Corp by 0.5% in the second quarter. Prudential Financial Inc. now owns 65,747 shares of the biopharmaceutical company’s stock valued at $3,255,000 after acquiring an additional 328 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in BioSpecifics Technologies Corp by 1.0% in the second quarter. American Century Companies Inc. now owns 30,461 shares of the biopharmaceutical company’s stock valued at $1,508,000 after acquiring an additional 302 shares during the last quarter. 55.36% of the stock is currently owned by institutional investors.
BioSpecifics Technologies Corp (NASDAQ BSTC) opened at $43.63 on Friday. The stock has a market cap of $313.66, a P/E ratio of 27.44 and a beta of 1.64. BioSpecifics Technologies Corp has a one year low of $41.95 and a one year high of $58.79.
BioSpecifics Technologies Corp (NASDAQ:BSTC) last announced its quarterly earnings data on Friday, November 10th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.01. The business had revenue of $6.52 million for the quarter, compared to analysts’ expectations of $6.59 million. BioSpecifics Technologies Corp had a net margin of 43.06% and a return on equity of 20.65%. equities analysts anticipate that BioSpecifics Technologies Corp will post 1.59 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Teachers Advisors LLC Acquires 1,305 Shares of BioSpecifics Technologies Corp (BSTC)” was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/12/teachers-advisors-llc-acquires-1305-shares-of-biospecifics-technologies-corp-bstc.html.
A number of research analysts recently issued reports on BSTC shares. HC Wainwright set a $72.00 price objective on shares of BioSpecifics Technologies Corp and gave the company a “buy” rating in a research note on Thursday, August 10th. BidaskClub cut shares of BioSpecifics Technologies Corp from a “sell” rating to a “strong sell” rating in a research note on Friday, August 18th. Finally, Zacks Investment Research cut shares of BioSpecifics Technologies Corp from a “hold” rating to a “strong sell” rating in a research note on Friday, August 11th.
BioSpecifics Technologies Corp Company Profile
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Want to see what other hedge funds are holding BSTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioSpecifics Technologies Corp (NASDAQ:BSTC).
Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.